Literature DB >> 17682102

Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location.

Johan Van Eldere1, Robertino M Mera, Linda A Miller, James A Poupard, Heather Amrine-Madsen.   

Abstract

We investigated the impact of the usage of antibiotics in ambulatory patients in Belgium in 147 defined geographical circumscriptions and at the individual isolate level. The study included 14,448 Streptococcus pneumoniae strains collected by the Belgium national reference lab from 1994 to 2004. Additional risk factors for resistance, such as population density/structure and day care attendance, were investigated for the same time-space window. A statistical model that included resistance to two or more antimicrobial classes offered the best fit for measuring the changes in nonsusceptibility to penicillin, macrolides, and tetracycline over time and place in Belgium. Analysis at the geographic level identified antimicrobial consumption with a 1-year lag (0.5% increase per additional defined daily dose) and population density as independent predictors of multiple resistance. Independent risk factors at the isolate level were age (odds ratio [OR], 1.55 for children aged <5 years), population density (7% increase in multiple resistance per 100 inhabitants/km(2)), conjugate 7-valent vaccine serotype (OR, 14.3), location (OR, 1.55 for regions bordering high-resistance France), and isolate source (OR, 1.54 for ear isolates). The expansion of multiple-resistant strains explains most of the overall twofold increase and subsequent decrease in single antimicrobial resistance between 1994 and 2004. We conclude that factors in addition to antibiotic use, such as high population density and proximity to high-resistance regions, favor multiple resistance. Regional resistance rates are not linearly related to actual antibiotic use but are linked to past antibiotic use plus a combination of demographic and geographic factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682102      PMCID: PMC2043272          DOI: 10.1128/AAC.01581-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Association between antibiotic sales and public campaigns for their appropriate use.

Authors:  Isabelle Bauraind; José-Maria Lopez-Lozano; Arielle Beyaert; Jean-Louis Marchal; Bruno Seys; Fernande Yane; Erik Hendrickx; Herman Goossens; Paul M Tulkens; Ludo Verbist
Journal:  JAMA       Date:  2004-11-24       Impact factor: 56.272

Review 2.  Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.

Authors:  D M Musher
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

3.  Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era.

Authors:  William P Hanage; Susan S Huang; Marc Lipsitch; Cynthia J Bishop; Daniel Godoy; Stephen I Pelton; Richard Goldstein; Heather Huot; Jonathan A Finkelstein
Journal:  J Infect Dis       Date:  2006-12-27       Impact factor: 5.226

4.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

5.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

6.  Global surveillance through PROTEKT: the first year.

Authors:  R N Grüneberg
Journal:  J Chemother       Date:  2002-07       Impact factor: 1.714

7.  A European study on the relationship between antimicrobial use and antimicrobial resistance.

Authors:  Stef L A M Bronzwaer; Otto Cars; Udo Buchholz; Sigvard Mölstad; Wim Goettsch; Irene K Veldhuijzen; Jacob L Kool; Marc J W Sprenger; John E Degener
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 8.  Comparative antimicrobial susceptibility of respiratory tract pathogens.

Authors:  David Felmingham
Journal:  Chemotherapy       Date:  2004       Impact factor: 2.544

9.  A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project.

Authors:  D Felmingham; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

10.  Otitis media complications and treatment failures: implications of pneumococcal resistance.

Authors:  M D Poole
Journal:  Pediatr Infect Dis J       Date:  1995-04       Impact factor: 2.129

View more
  15 in total

1.  Evaluation of the Do Bugs Need Drugs? program in British Columbia: Can we curb antibiotic prescribing?

Authors:  Rachel M McKay; Linda Vrbova; Elaine Fuertes; Mei Chong; Samara David; Kim Dreher; Dale Purych; Edith Blondel-Hill; Bonnie Henry; Fawziah Marra; Perry Rw Kendall; David M Patrick
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

Review 2.  Antibiotic use and population ecology: how you can reduce your "resistance footprint".

Authors:  David M Patrick; James Hutchinson
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

3.  Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.

Authors:  Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  Outpatient Antibiotic Prescription.

Authors:  Jörg Bätzing-Feigenbaum; Maike Schulz; Mandy Schulz; Ramona Hering; Winfried V Kern
Journal:  Dtsch Arztebl Int       Date:  2016-07-01       Impact factor: 5.594

5.  Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis.

Authors:  Ina Willemsen; Ben Cooper; Carin van Buitenen; Marjolein Winters; Gunnar Andriesse; Jan Kluytmans
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 6.  Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.

Authors:  Ariel R Brumbaugh; Harry L T Mobley
Journal:  Expert Rev Vaccines       Date:  2012-06       Impact factor: 5.217

7.  Correlation between antibiotic use and resistance in a hospital: temporary and ward-specific observations.

Authors:  I Willemsen; D Bogaers-Hofman; M Winters; J Kluytmans
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

8.  Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004.

Authors:  Heather Amrine-Madsen; Johan Van Eldere; Robertino M Mera; Linda A Miller; James A Poupard; Elizabeth S Thomas; Wendy S Halsey; Julie A Becker; F Patrick O'Hara
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

Review 9.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

10.  Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial.

Authors:  Alison H Skalet; Vicky Cevallos; Berhan Ayele; Teshome Gebre; Zhaoxia Zhou; James H Jorgensen; Mulat Zerihun; Dereje Habte; Yared Assefa; Paul M Emerson; Bruce D Gaynor; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Med       Date:  2010-12-14       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.